Eisai, Biogen present data on lecanemab subcutaneous autoinjector. The companies presented their investigational SC-AI for lecanemab-irmb at the Alzheimer’s Association International Conference in Toronto. The results showed that the SC-AI maintenance dose maintains clinical and biomarker benefits similar to the intravenous formulation after 18 months of initial treatment. With a beta of -0.18, Eisai’s stock movements often counter market trends, offering potential portfolio diversification benefits. Eisai is developing the SC-AI as a maintenance treatment option following 18 months of IV therapy. The safety profile of SC-AI maintenance dosing was consistent with IV maintenance therapy, with fewer systemic injection reactions. Human factors studies demonstrated high success rates in administering SC doses, with high satisfaction levels reported. Eisai and Biogen are co-commercializing lecanemab globally, with regulatory reviews ongoing in several countries. The article also mentions Eisai’s fiscal year results, with projected operating profit and gross profit margin figures, and discusses the broader market context, including TSX and S&P 500 analysis.

Eisai, Biogen present data on lecanemab subcutaneous autoinjector

Eisai and Biogen presented data on their investigational subcutaneous autoinjector (SC-AI) for lecanemab-irmb at the Alzheimer’s Association International Conference in Toronto. The results showed the SC-AI maintenance dose maintained clinical and biomarker benefits similar to the intravenous formulation after 18 months of initial treatment. Eisai’s stock has a beta of -0.18, indicating potential portfolio diversification benefits. The companies are co-commercializing lecanemab globally, with regulatory reviews ongoing in multiple countries. The article also covers Eisai’s fiscal year results, including projected operating profit and gross profit margin figures, alongside broader market context involving TSX and S&P 500 analysis.